The Camp Lejeune Justice Act of 2022. Are you eligible for compensation?
BY: Jason J. Thompson | IN: Class Action & Commercial Litigation, Personal Injury
Takeda Pharmaceuticals Company Limited, together with its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., have agreed to pay $2.37 billion to resolve thousands of product liability lawsuits pending in the U.S. involving allegations that the companies’ prescription diabetes drug, Actos, caused cancer. The settlement seeks to resolve a collection of multidistrict litigation proceedings, the first trial of which resulted in a $9 billion verdict in April 2014 we previously reported.
If you or some you know was prescribed Actos and believe you have a claim, you should immediately speak with an attorney familiar with the settlement and litigation. The Master Settlement Agreement, available for viewing and download at www.actosofficialsettlement.com, has many conditions and eligibility requirements, the most important of which are:
To be included in the settlement, a preliminary census form must be on file by Friday, May 8, 2015.
To discuss your potential claim, please contact attorney Jason J. Thompson of Sommers Schwartz as soon as possible if you suspect you have been injured by the Actos drug.
View all posts byJason J. Thompson
Jason Thompson is a nationally board certified trial attorney and co-chairs Sommers Schwartz’s Complex Litigation Department. He has a formidable breadth of litigation experience, including class action and multidistrict litigation (MDL), and practices nationwide in both state and federal courts.